# Treatment of West Nile Virus With MGAWN1

> **NCT00927953** · PHASE2 · TERMINATED · sponsor: **MacroGenics** · enrollment: 13 (actual)

## Conditions studied

- West Nile Neuroinvasive Disease
- West Nile Virus Infection
- Encephalitis
- Meningitis
- Acute Flaccid Paralysis
- West Nile Fever

## Interventions

- **BIOLOGICAL:** MGAWN1
- **BIOLOGICAL:** Placebo - normal saline

## Key facts

- **NCT ID:** NCT00927953
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2011-02
- **Final completion:** 2011-05
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Early termination due to the inability to enroll (13 of 120 subjects enrolled)
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927953, "Treatment of West Nile Virus With MGAWN1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00927953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*